The overuse of antibiotics is widely recognized as one of the main factors contributing to antimicrobial resistance (AMR), often called the “silent pandemic,” but what is less well-known is that shortages of antibiotics also play a role in fueling it.
Scarce supplies of pediatric amoxicillin, used to treat Strep A, made headlines in the UK late last year, as a surge of infections left at least 19 children dead. From being an outlier, such shortfalls are common and pervasive, affecting countries across the world, and their consequences for individuals’ health and AMR’s spread can be dire.
That is because shortages of first-line antibiotics often lead to overuse of those that are specialized or kept in reserve for emergencies. Not only can these substitutes be less effective, but reliance on them increases the risk of drug resistance developing and infections becoming more difficult to treat in the long-run.
Illustration: Mountain People
Already one of the world’s biggest killers, AMR is on the rise. In 2019, it was directly responsible for an estimated 1.27 million deaths — more than HIV/AIDS and malaria combined — and associated with 4.95 million more.
So far, the global response to this growing crisis has focused mainly on trying to outpace drug-resistant bacteria through the development of new antibiotics.
Yet in the short term, there is ample room to reduce the number of AMR deaths, as well as AMR’s impact on health more broadly, by addressing some of the causes of shortages and improving access to appropriate treatments.
The same market failures that triggered the global AMR crisis are also largely responsible for antibiotic shortages. Compared with other drugs, antibiotics are often more complex and more costly to manufacture, have stricter regulatory requirements and are less profitable. As a result, many pharmaceutical companies have significantly reduced or stopped antibiotic research and development over the past few decades.
Not only are very few new antibiotics being developed, but it has also become less attractive to produce those already on the market, partly due to supply chain bottlenecks and volatility. All it takes is a disruption in the supply of an ingredient or a quality-control problem, or a supplier increasing prices or halting production entirely, to bring the global supply chain of these medicines to a standstill.
Just as important has been the equally volatile demand for antibiotics caused by sudden outbreaks of bacterial infections and poor management of national supplies, which contributes to stockouts. While shortages are not uncommon in the pharmaceutical industry, they are 42 percent more likely for antibiotics than they are for other drugs.
Although precise numbers that would reveal the scale of the problem are difficult to obtain, much of this uncertainty could be avoided with better market intelligence. Even though antibiotics are less lucrative than other drugs, pharmaceutical companies can still turn a profit — if they have accurate data. Improved forecasting can thus reduce risks for manufacturers and provide them with an incentive to scale up production and expand their markets.
There is also plenty of room for improvement in the way that countries — particularly lower-income nations — procure, register and manage these vital drugs.
For example, by expanding the capacity of national regulatory authorities, it would be easier to track and coordinate supplies and create stockpiles to build greater resilience. All of this would also help provide more certainty for drugmakers.
SECURE, an initiative led by the WHO and the Global Antibiotic Research and Development Partnership (of which I am executive director), aims to work with countries to improve access to essential antibiotics. That involves exploring how national regulatory authorities could serve as centralized hubs to help monitor, prevent and respond to shortages.
Eventually, SECURE intends to create more buoyant and competitive markets by encouraging countries to pool procurement, ensuring a more reliable supply.
Shortages of antibiotics are a serious problem for all countries, but there is plenty that can — and should — be done to prevent them. Given the accelerating spread of AMR and the long lead-in time to develop antibiotics, the problem can no longer be overlooked.
Equally important, efforts to address scarce supplies could help ensure that, when new drugs become available, they reach the people who need them.
Manica Balasegaram is executive director of the Global Antibiotic Research and Development Partnership.
Copyright: Project Syndicate
The Chinese Communist Party (CCP) continues to bully Taiwan by conducting military drills extremely close to Taiwan in late May 2024 and announcing a legal opinion in June on how they would treat “Taiwan Independence diehards” according to the PRC’s Criminal Code. This article will describe how China’s Anaconda Strategy of psychological and legal asphyxiation is employed. The CCP’s People’s Liberation Army (PLA) and Chinese Coast Guard (CCG) conducted a “punishment military exercise” against Taiwan called “Joint Sword 2024A” from 23-24 May 2024, just three days after President William Lai (賴清德) of the Democratic Progressive Party (DPP) was sworn in and
Former US president Donald Trump’s comments that Taiwan hollowed out the US semiconductor industry are incorrect. That misunderstanding could impact the future of one of the world’s most important relationships and end up aiding China at a time it is working hard to push its own tech sector to catch up. “Taiwan took our chip business from us,” the returnee US presidential contender told Bloomberg Businessweek in an interview published this week. The remarks came after the Republican nominee was asked whether he would defend Taiwan against China. It is not the first time he has said this about the nation’s
The Yomiuri Shimbun, the newspaper with the largest daily circulation in Japan, on Thursday last week published an article saying that an unidentified high-ranking Japanese official openly spoke of an analysis that the Chinese People’s Liberation Army (PLA) needs less than a week, not a month, to invade Taiwan with its amphibious forces. Reportedly, Japanese Prime Minister Fumio Kishida has already been advised of the analysis, which was based on the PLA’s military exercises last summer. A Yomiuri analysis of unclassified satellite photographs confirmed that the PLA has already begun necessary base repairs and maintenance, and is conducting amphibious operation exercises
The first session of the 11th Legislative Yuan’s four-year term ended on Tuesday, and 55 bills were passed in the session, which is the fewest bills passed in one session in 12 years. However, Legislative Speaker Han Kuo-yu (韓國瑜) said the session delivered a “very good result,” despite there being fights and arguments in this break-in session for many newly elected legislators. In the last two days of the session, lawmakers rushed to pass a slew of resolutions and bills, mainly proposed by opposition Chinese Nationalist Party (KMT) and Taiwan People’s Party (TPP) legislators, who have a combined majority in the